The main objective is the recognition of different AATD clinical phenotypes by cluster analysis in baseline EARCO data.
In a second stage, these clusters could be linked to clinically relevant outcomes such as lung function decline and exacerbations.
Baseline data from the EARCO registry will be used. All registered patients from the launch in february 2020 to start of analysis will be eligible for cluster analysis.
Baseline data from the EARCO registry will be used for cluster analysis. Different methods will be tested to obtain the best model. Cluster analyses are useful to recognize different clinical phenotypes and to discover associations between different clinical features. This is useful since AATD is a very heterogeneous disease, even within the same genotype.